Table 1.
Case characteristics of patients with hair loss after COVID-19 vaccination.
| N. | Sex | Age (Years) | Ethnicity | Family History | Personal History | Vaccine Received | Symptoms | Post-Vaccination Onset Time | Therapy | Evolution |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 27 | Mestizo | No | AU, Polycystic ovary | Pfizer, SinoVac, and AstraZeneca (Booster) | Alopecia universalis | 8 days | Mesotherapy and pulses of dexamethasone and Clobetasol propionate 0.5% topical | 25% |
| 2 | F | 51 | Mestizo | Hypothyroidism (grandmother) | AH | Pfizer, SinoVac, and AstraZeneca (Booster) | Telogen effluvium | 3 days | Mesotherapy | 80% |
| 3 | M | 34 | Mestizo | DM 2, AH (grandmother) | COVID-19 | Pfizer, SinoVac, and AstraZeneca (Booster) | Telogen effluvium | 10 days | Mesotherapy | 50% |
| 4 | M | 40 | Mestizo | No | COVID-19 | Pfizer, SinoVac, and AstraZeneca (Booster) | Telogen effluvium | 7 days | Mesotherapy | 90% |
| 5 | M | 59 | Mestizo | No | AH, COVID-19 | Pfizer, SinoVac, and AstraZeneca (Booster) | Alopecia universalis | 17 days | Mesotherapy and pulses of dexamethasone and Clobetasol propionate 0.5% topical | 15% |
F: female; M: male; AU: alopecia universalis; DM 2: diabetes mellitus type 2; AH: arterial hypertension.